ArticleJAMA network open2026
Diagnostic Value and Outcomes of Systematic SARS-CoV-2 Screening in Asymptomatic Patients.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial: Emergence of Cicada (BA.3.2) SARS-CoV-2 and the Implications for COVID-19 Surveillance and Monitoring.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Early detection of SARS-CoV-2 may mitigate nosocomial spread, yet universal screening of asymptomatic patients remains debated. Objective: To evaluate the diagnostic yield of systematic SARS-CoV-2 screening in correlation with community incidence and wastewater viral load and assess clinical outcomes among inpatients with false-positive results. Design, Setting, and Participants: This retrospective quality-control cohort study assessed the results of systematic SARS-CoV-2 screening of asymptomatic patients at the University Hospital Basel in Basel, Switzerland, a tertiary care center admitting more than 40 000 adult patients annually. All patients with systematic screenings for SARS-CoV-2 infection from February 8, 2021, to July 5, 2021, and from August 25, 2021, to December 5, 2022, were included. Data were analyzed from January 2024 to February 2025. Exposure: Saliva-based PCR-tests to screen for asymptomatic SARS-CoV-2 infection on admission and at regular 3- to 5-day intervals during hospitalization. Main Outcomes and Measures: The primary end points were the proportion of positive and false-positive SARS-CoV-2 test results, as well as the number needed to screen to find 1 otherwise undetected SARS-CoV-2 infection. Clinical data and test results were analyzed along with community incidence and wastewater viral loads. Correlations were calculated using Spearman test, and clinical implications of false-positive results were assessed. Results: Among 75 667 screening tests performed on 42 666 patients (21 591 [50.6%] female; median [IQR] age, 64 [45-76] years), 761 patients (1.2% of tests) had positive results. These were classified as true-positive results in 483 patients (63.5%) and false-positive results in 278 patients (36.5%). Among patients with false-positive test results, 139 patients (50.0%) experienced unnecessary isolation, 46 patients (16.5%) were exposed to patients with true-positive SARS-CoV-2 test results by cohorting, and 9 patients (3.2%) received delayed interventions. Screening test positivity correlated with local incidence of SARS-CoV-2 infections and wastewater viral loads. A total of 93.7% of positive test results were recorded during weeks with high community incidence (ie, >150 events per 100 000 inhabitants), in which the proportion of patients with false-positive test results was lower (249 of 709 patients [35.1%]) compared with weeks with low community incidence (ie, <150 events 100 000 inhabitants), with 29 of 52 patients (55.8%) having false-positive results. Conclusions and Relevance: In this cohort study, universal SARS-CoV-2 screening detected asymptomatic carriers of SARS-CoV-2 infection, aligned with community incidence, and thus may support infection prevention and control measures. However, the unintended clinical outcomes, particularly during times of low incidence, necessitate careful contextual implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.